当前位置: X-MOL 学术Front. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma
Frontiers in Oncology ( IF 4.7 ) Pub Date : 2022-09-27 , DOI: 10.3389/fonc.2022.963096
Tianyu Dong 1, 2 , Bo Zhang 1 , Runjiao Zhang 2 , Chang Wang 2 , Xiaopeng Liu 1, 3 , Fei Wang 1 , Nana Hao 4 , Ke Tan 1 , Yan-Zhong Chang 1
Affiliation  

Background

Glioma is the most common primary malignant brain tumor with high mortality and poor prognosis. Hepcidin is a fascinating iron metabolism regulator. However, the prognostic value of hepcidin HAMP in gliomas and its correlation with immune cell infiltration remain unclear. Here, we comprehensively elucidate the prognostic value and potential role of hepcidin in gliomas.

Methods

Hepcidin gene expression and clinical characteristics in glioma were analyzed using the CGGA, TCGA, Rembrandt and Gravendeel glioma databases. A survival analysis was conducted using Kaplan–Meier and Cox regression analyses. A gene set enrichment analysis (GSEA) was conducted to select the pathways significantly enriched for hepcidin associations. The correlations between hepcidin and immune cell infiltration and immunotherapy were analyzed using network platforms such as CIBERSORT and TIMER.

Results

In glioma tissues, the expression of hepcidin was significantly increased. High hepcidin expression is related to grade, age, PRS type, IDH mutation, chemotherapy status and 1p19q codeletion status, which significantly indicates the poor prognosis of glioma patients. Hepcidin can be used as an independent prognostic factor for glioma through the multivariate COX regression analysis. The results of Gene Ontology (GO), Kyoto Encyclopedia of Gene and Genome (KEGG) and gene set enrichment analysis (GSEA) indicated that hepcidin was involved in the immune response. In addition, hepcidin expression was positively correlated with the degree of immune cell infiltration, the expression of various immune cell markers and the efficacy of immunotherapy.

Conclusion

Our results indicate that hepcidin can be used as a candidate biomarker to judge the prognosis and immune cell invasion of gliomas.



中文翻译:

铁调素被上调并且是与神经胶质瘤免疫相关的潜在治疗靶点

Background

胶质瘤是最常见的原发性恶性脑肿瘤,死亡率高,预后差。Hepcidin 是一种迷人的铁代谢调节剂。然而,铁调素 HAMP 在神经胶质瘤中的预后价值及其与免疫细胞浸润的相关性仍不清楚。在这里,我们全面阐明了铁调素在神经胶质瘤中的预后价值和潜在作用。

Methods

使用 CGGA、TCGA、Rembrandt 和 Gravendeel 神经胶质瘤数据库分析神经胶质瘤中的铁调素基因表达和临床特征。使用 Kaplan–Meier 和 Cox 回归分析进行生存分析。进行基因集富集分析 (GSEA) 以选择显着富集铁调素关联的途径。利用 CIBERSORT 和 TIMER 等网络平台分析铁调素与免疫细胞浸润和免疫治疗的相关性。

Results

In glioma tissues, the expression of hepcidin was significantly increased. High hepcidin expression is related to grade, age, PRS type, IDH mutation, chemotherapy status and 1p19q codeletion status, which significantly indicates the poor prognosis of glioma patients. Hepcidin can be used as an independent prognostic factor for glioma through the multivariate COX regression analysis. The results of Gene Ontology (GO), Kyoto Encyclopedia of Gene and Genome (KEGG) and gene set enrichment analysis (GSEA) indicated that hepcidin was involved in the immune response. In addition, hepcidin expression was positively correlated with the degree of immune cell infiltration, the expression of various immune cell markers and the efficacy of immunotherapy.

Conclusion

我们的研究结果表明铁调素可以作为判断胶质瘤预后和免疫细胞侵袭的候选生物标志物。

更新日期:2022-09-27
down
wechat
bug